- ISIN
- US00901B1052
- CUSIP
- 00901B105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 12, 1996
Highlights
- Market Cap
- $12.01M
- Enterprise Value
- $6.81M
- EPS (TTM)
- -$4.57
- Total Revenue (TTM)
- $94.00K
- Gross Profit (TTM)
- -$143.00K
- EBITDA (TTM)
- -$8.14M
- Year Range
- $2.73 - $2.88
- ROA (TTM)
- -154.64%
- ROE (TTM)
- -624.75%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AIM Performance Chart
Loading charts...
Returns By Period
AIM ImmunoTech Inc.
- 1D
- -1.08%
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
AIM Monthly Returns History
Based on dividend-adjusted daily data since Jun 4, 2026, AIM's average daily return is +0.23%, while the average monthly return is +1.10%. At this rate, an investment would double in approximately 5.3 years.
Historically, 100% of months were positive and 0% were negative. The best month was Jun 2026 with a return of +1.1%, while the worst month was Jun 2026 at 1.1%. The longest winning streak lasted 1 consecutive months, and the longest losing streak was 0 months.
On a daily basis, AIM closed higher 40% of trading days. The best single day was Jun 9, 2026 with a return of +2.0%, while the worst single day was Jun 8, 2026 at -1.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.10% | 1.10% |
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for AIM ImmunoTech Inc. (AIM) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AIM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | — | 1.37 | — |
| Calmar ratioReturn relative to maximum drawdown | — | 2.78 | — |
| Martin ratioReturn relative to average drawdown | — | 12.44 | — |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the AIM ImmunoTech Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the AIM ImmunoTech Inc. was 1.62%, occurring on Jun 8, 2026. Recovery took 1 trading session.
The current AIM ImmunoTech Inc. drawdown is 1.08%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 pullback2026 | -1.62%Jun 2026 | 3d | 1d | 4dJun 2026 - Jun 2026 |
2026 pullback2026 | -1.08%Jun 2026 | 0s | — | 13d 17hJun 2026 - now |
Drawdown Indicators
| AIM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -1.62% | -56.78% | +55.16% |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -1.08% | -1.80% | +0.72% |
Average DrawdownAverage peak-to-trough decline | -0.61% | -10.71% | +10.10% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 2.03% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of AIM ImmunoTech Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how AIM ImmunoTech Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AIM relative to other companies in the Biotechnology industry. Currently, AIM has a P/S ratio of 85.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AIM in comparison with other companies in the Biotechnology industry. Currently, AIM has a P/B value of 5.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AIM
Add AIM ImmunoTech Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AIM